Search

Objective Optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation remains controversial. The present study is an assessment of efficacy and safety of short-term (≤6 months) DAPT after DES implantation in patients with coronary artery disease, especially in important subgroups. Methods PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched for randomized, controlled trials comparing short-term and long-term (>6 months) DAPT after DES implantation. Primary efficacy outcome was stent thrombosis (ST). Primary safety outcome was major bleeding. Pooled relative risks (RRs) with 95% confidence interval (CI) were calculated using random- or fixed-effects models as appropriate. Results Total of 7 trials involving 15870 patients were included in the study. Short-term DAPT significantly reduced major bleeding by 49% compared with long-term DAPT (RR: 0.51; 95% CI: 0.32-0.80; p=0.003) without increasing risk of ST (RR: 1.28; 95% CI: 0.83-1.97; p=0.266). In addition, no differences were observed in all-cause mortality, myocardial infarction (MI), cardiac mortality, or cerebrovascular accidents. Moreover, no significant difference in composite of cardiovascular events, bleeding, and mortality was found in important clinical subgroups. Conclusion Short-term DAPT is associated with lower bleeding risk compared with long-term DAPT. Number of ST and MI was higher with short-term DAPT without reaching statistical significance. Comprehensive clinical judgment is necessary to weigh benefits and risks in the individual patient.

Yan Kuang,1 Fangfang Lu,1 Jianfeng Guo,2 Hong Xu,1 Qi Wang,1 Chaohuan Xu,1 Longjia Zeng,1 Suyi Yi1 1Department of Obstetrics and Gynecology, First Affiliated Hospital of Guangxi Medical University, Nanning, 2Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China Abstract: Aberrant histone methylation contributes to the progression and development of many tumors. Histone methylation is a dynamic process regulated by both histone demethylase and histone methyltransferase, which ultimately alters the levels of gene transcription. However, the relationship between histone demethylase and histone methyltransferase, as well as their regulatory mechanisms in ovarian cancer development, is still unclear. Lysine-specific demethylase 2B (KDM2B) is a key demethylase of H3K36me3 and H3K4me3 that regulates gene expression and plays a role in tumorigenesis via epigenetic mechanisms. To determine the expression pattern of KDM2B in ovarian neoplasms, we analyzed the mRNA and protein levels of KDM2B and the histone methyltransferase enhancer of zester homolog 2 (EZH2) in normal, benign, borderline, and malignant ovarian tissue samples. We found that KDM2B expression was gradually increased in ovarian tumors, with the highest expression found in the malignant ovarian tissues, and the differences in KDM2B expression among the different International Federation of Gynecology and Obstetrics stages and pathological grades/types were statistically significant. Moreover, KDM2B expression was positively correlated with EZH2 expression in ovarian tissues. To determine the role of KDM2B in tumorigenesis in vitro and in vivo, we silenced KDM2B expression in ovarian cancer cells using the KDM2B short hairpin RNA expression lentivirus and established a nude mouse xenograft model. Downregulation of endogenous KDM2B decreased the expression of EZH2 and reduced the proliferation and migration of ovarian cancer cells. Loss of KDM2B suppressed ovarian tumor formation in vivo. Our results suggest that KDM2B plays an important role in the tumorigenesis of ovarian cancer, with a possible mechanism of increasing the expression of the oncogene EZH2; this indicates that certain histone methyltransferase may be positively regulated by certain histone demethylase in the epigenetic regulation of ovarian tumors. KDM2B may be a novel therapeutic target for the clinical treatment of ovarian cancer. Keywords: ovarian cancer, KDM2B, EZH2, epigenetic regulation, tumor formation&nbsp

The value of neoadjuvant chemotherapy (NAC) has not yet been fully defined. We aimed to systematically evaluate the influence of neoadjuvant chemotherapy (NAC) on survival and complete cytoreduction after debulking surgery in advanced epithelial ovarian cancer (AEOC) patients. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for the randomized controlled trials (RCTs) comparing NAC and primary debulking surgery (PDS) in AEOC patients. The last search date is February 25, 2016. Cochrane systematic evaluation was used to evaluate bias risk of included studies. RevMan 5.3 software was used for statistical analysis. A total of 4 RCTs involving 1922 patients were included. Compared with PDS, NAC may contribute to the completeness of debulking removal [no residual disease (RR: 2.37; 95%CI: 1.94–2.91; P

A new approach on usage of S-1-dodecyl-S'-(α,α'-dimethyl-α"-acetic acid)trithiocarbonate (DDAT)-covalently functionalized graphene oxide (GO) as reversible addition fragmentation chain transfer (RAFT) agent for growing of poly(N-vinylcarbazole) (PVK) directly from the surface of GO was described. The PVK polymer covalently grafted onto GO has M n of 8.05 x 10 3 , and a polydispersity of 1.43. The resulting material PVK-GO shows a good solubility in organic solvents when compared to GO, and a significant energy bandgap of ~2.49 eV. Bistable electrical switching and nonvolatile rewritable memory effect, with a turn-on voltage of about -1.7 V and an ON/OFF state current ratio in excess of 10 3 , are demonstrated in the AI/PVK-GO/ITO structure.

Bistable electrical conductivity switching and non-volatile memory effects were demonstrated in Al/polymer/indium-tin oxide sandwich structure devices, constructed from two poly(N-vinylcarbazole) derivatives with pendant azobenzene chromophores and terminal electron acceptor moieties (–NO2 or –CN). Both polymers (PVK-AZO-NO2 and PVK-AZO-2CN) exhibit write-once read-many-times (WORM) type memory effects, with low switching threshold voltages below −2 V and high ON/OFF current ratios of ∼105–106. The observed electrical bistability in both polymers can be attributed to the field-induced charge transfer interaction between carbazole electron donor and terminal electron acceptor (–NO2 or –CN) moieties, and subsequent charge trapping at the intermediate azobenzene chromophores. The proposed switching mechanism is supported by the changes in the UV-visible absorption spectra of the polymer film upon transition from the OFF to the ON state.